The therapeutic potential of ERBB3 inhibitors, such as AZD8931, demonstrates that TFE3-RCC cells lacking ARID2 are more sensitive to this treatment, providing promising directions for improving outcomes for patients with this aggressive cancer subtype. This evidence concerns the gene ARID2 and cancer.